EASL recommendations on treatment of hepatitis C: Final update of the series

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hepatology 2020-11, Vol.73 (5), p.1170-1218
Main Authors: Pawlotsky, Jean-Michel, Negro, Francesco, Aghemo, Alessio, Berenguer, Marina, Dalgard, Olav, Dusheiko, Geoffrey, Marra, Fiona, Puoti, Massimo, Wedemeyer, Heiner
Format: Article
Language:English
Subjects:
Chronic infection
Hepatitis C
Interferon
Liver diseases
Patients
Public health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c494t-4f385e039712fd00103ad9f2afdc0cd75b99512d094b1174ecbd58f782465f203
cites cdi_FETCH-LOGICAL-c494t-4f385e039712fd00103ad9f2afdc0cd75b99512d094b1174ecbd58f782465f203
container_end_page 1218
container_issue 5
container_start_page 1170
container_title Journal of hepatology
container_volume 73
creator Pawlotsky, Jean-Michel
Negro, Francesco
Aghemo, Alessio
Berenguer, Marina
Dalgard, Olav
Dusheiko, Geoffrey
Marra, Fiona
Puoti, Massimo
Wedemeyer, Heiner
description Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, as well as developments in diagnostic procedures and improvements in therapy and prevention. These therapies make it possible to eliminate hepatitis C as a major public health threat, as per the World Health Organization target, although the timeline and feasibility vary from region to region. These European Association for the Study of the Liver recommendations on treatment of hepatitis C describe the optimal management of patients with recently acquired and chronic HCV infections in 2020 and onwards.
doi_str_mv 10.1016/j.jhep.2020.08.018
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2444873987</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168827820305481</els_id><sourcerecordid>2486864333</sourcerecordid><originalsourceid>FETCH-LOGICAL-c494t-4f385e039712fd00103ad9f2afdc0cd75b99512d094b1174ecbd58f782465f203</originalsourceid><addsrcrecordid>eNp9kE1r3DAQhkVpSTbb_IEeiqCXXOyOZNmWQy9hyUdhoYekZ-GVRkRmbW0lOZB_H5lNcughAiHQPPOO9BDyjUHJgDU_h3J4xEPJgUMJsgQmP5EVawAKaAT7TFYZkoXkrTwlZzEOAFBBJ07IacW7umkbuSLb66v7LQ2o_TjiZPrk_BSpn2gK2Kd8lai3NI_JleQi3VzSGzf1ezofMoxLMT0ijRgcxq_ki-33Ec9fzzX5e3P9sLkrtn9uf2-utoUWnUiFsJWsEaquZdwaAAZVbzrLe2s0aNPWu66rGTf5rTvGWoF6Z2ppW8lFU1sO1ZpcHHMPwf-bMSY1uqhxv-8n9HNUXAgh26rLe01-_IcOfg75AwslG9mIKq814UdKBx9jQKsOwY19eFYM1OJaDWpxrRbXCqTKrnPT99foeTeieW95k5uBX0cAs4snh0FF7XDSaFwWnpTx7qP8F9nIjcc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2486864333</pqid></control><display><type>article</type><title>EASL recommendations on treatment of hepatitis C: Final update of the series</title><source>ScienceDirect Journals</source><creator>Pawlotsky, Jean-Michel ; Negro, Francesco ; Aghemo, Alessio ; Berenguer, Marina ; Dalgard, Olav ; Dusheiko, Geoffrey ; Marra, Fiona ; Puoti, Massimo ; Wedemeyer, Heiner</creator><creatorcontrib>Pawlotsky, Jean-Michel ; Negro, Francesco ; Aghemo, Alessio ; Berenguer, Marina ; Dalgard, Olav ; Dusheiko, Geoffrey ; Marra, Fiona ; Puoti, Massimo ; Wedemeyer, Heiner ; Clinical Practice Guidelines Panel: Chair ; European Association for the Study of the Liver ; Panel members ; EASL Governing Board representative ; European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu</creatorcontrib><description>Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, as well as developments in diagnostic procedures and improvements in therapy and prevention. These therapies make it possible to eliminate hepatitis C as a major public health threat, as per the World Health Organization target, although the timeline and feasibility vary from region to region. These European Association for the Study of the Liver recommendations on treatment of hepatitis C describe the optimal management of patients with recently acquired and chronic HCV infections in 2020 and onwards.</description><identifier>ISSN: 0168-8278</identifier><identifier>EISSN: 1600-0641</identifier><identifier>DOI: 10.1016/j.jhep.2020.08.018</identifier><identifier>PMID: 32956768</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Chronic infection ; Hepatitis C ; Interferon ; Liver diseases ; Patients ; Public health</subject><ispartof>Journal of hepatology, 2020-11, Vol.73 (5), p.1170-1218</ispartof><rights>2020 European Association for the Study of the Liver</rights><rights>Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Nov 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c494t-4f385e039712fd00103ad9f2afdc0cd75b99512d094b1174ecbd58f782465f203</citedby><cites>FETCH-LOGICAL-c494t-4f385e039712fd00103ad9f2afdc0cd75b99512d094b1174ecbd58f782465f203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32956768$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pawlotsky, Jean-Michel</creatorcontrib><creatorcontrib>Negro, Francesco</creatorcontrib><creatorcontrib>Aghemo, Alessio</creatorcontrib><creatorcontrib>Berenguer, Marina</creatorcontrib><creatorcontrib>Dalgard, Olav</creatorcontrib><creatorcontrib>Dusheiko, Geoffrey</creatorcontrib><creatorcontrib>Marra, Fiona</creatorcontrib><creatorcontrib>Puoti, Massimo</creatorcontrib><creatorcontrib>Wedemeyer, Heiner</creatorcontrib><creatorcontrib>Clinical Practice Guidelines Panel: Chair</creatorcontrib><creatorcontrib>European Association for the Study of the Liver</creatorcontrib><creatorcontrib>Panel members</creatorcontrib><creatorcontrib>EASL Governing Board representative</creatorcontrib><creatorcontrib>European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu</creatorcontrib><title>EASL recommendations on treatment of hepatitis C: Final update of the series</title><title>Journal of hepatology</title><addtitle>J Hepatol</addtitle><description>Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, as well as developments in diagnostic procedures and improvements in therapy and prevention. These therapies make it possible to eliminate hepatitis C as a major public health threat, as per the World Health Organization target, although the timeline and feasibility vary from region to region. These European Association for the Study of the Liver recommendations on treatment of hepatitis C describe the optimal management of patients with recently acquired and chronic HCV infections in 2020 and onwards.</description><subject>Chronic infection</subject><subject>Hepatitis C</subject><subject>Interferon</subject><subject>Liver diseases</subject><subject>Patients</subject><subject>Public health</subject><issn>0168-8278</issn><issn>1600-0641</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kE1r3DAQhkVpSTbb_IEeiqCXXOyOZNmWQy9hyUdhoYekZ-GVRkRmbW0lOZB_H5lNcughAiHQPPOO9BDyjUHJgDU_h3J4xEPJgUMJsgQmP5EVawAKaAT7TFYZkoXkrTwlZzEOAFBBJ07IacW7umkbuSLb66v7LQ2o_TjiZPrk_BSpn2gK2Kd8lai3NI_JleQi3VzSGzf1ezofMoxLMT0ijRgcxq_ki-33Ec9fzzX5e3P9sLkrtn9uf2-utoUWnUiFsJWsEaquZdwaAAZVbzrLe2s0aNPWu66rGTf5rTvGWoF6Z2ppW8lFU1sO1ZpcHHMPwf-bMSY1uqhxv-8n9HNUXAgh26rLe01-_IcOfg75AwslG9mIKq814UdKBx9jQKsOwY19eFYM1OJaDWpxrRbXCqTKrnPT99foeTeieW95k5uBX0cAs4snh0FF7XDSaFwWnpTx7qP8F9nIjcc</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Pawlotsky, Jean-Michel</creator><creator>Negro, Francesco</creator><creator>Aghemo, Alessio</creator><creator>Berenguer, Marina</creator><creator>Dalgard, Olav</creator><creator>Dusheiko, Geoffrey</creator><creator>Marra, Fiona</creator><creator>Puoti, Massimo</creator><creator>Wedemeyer, Heiner</creator><general>Elsevier B.V</general><general>Elsevier Science Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>202011</creationdate><title>EASL recommendations on treatment of hepatitis C: Final update of the series</title><author>Pawlotsky, Jean-Michel ; Negro, Francesco ; Aghemo, Alessio ; Berenguer, Marina ; Dalgard, Olav ; Dusheiko, Geoffrey ; Marra, Fiona ; Puoti, Massimo ; Wedemeyer, Heiner</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c494t-4f385e039712fd00103ad9f2afdc0cd75b99512d094b1174ecbd58f782465f203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Chronic infection</topic><topic>Hepatitis C</topic><topic>Interferon</topic><topic>Liver diseases</topic><topic>Patients</topic><topic>Public health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pawlotsky, Jean-Michel</creatorcontrib><creatorcontrib>Negro, Francesco</creatorcontrib><creatorcontrib>Aghemo, Alessio</creatorcontrib><creatorcontrib>Berenguer, Marina</creatorcontrib><creatorcontrib>Dalgard, Olav</creatorcontrib><creatorcontrib>Dusheiko, Geoffrey</creatorcontrib><creatorcontrib>Marra, Fiona</creatorcontrib><creatorcontrib>Puoti, Massimo</creatorcontrib><creatorcontrib>Wedemeyer, Heiner</creatorcontrib><creatorcontrib>Clinical Practice Guidelines Panel: Chair</creatorcontrib><creatorcontrib>European Association for the Study of the Liver</creatorcontrib><creatorcontrib>Panel members</creatorcontrib><creatorcontrib>EASL Governing Board representative</creatorcontrib><creatorcontrib>European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pawlotsky, Jean-Michel</au><au>Negro, Francesco</au><au>Aghemo, Alessio</au><au>Berenguer, Marina</au><au>Dalgard, Olav</au><au>Dusheiko, Geoffrey</au><au>Marra, Fiona</au><au>Puoti, Massimo</au><au>Wedemeyer, Heiner</au><aucorp>Clinical Practice Guidelines Panel: Chair</aucorp><aucorp>European Association for the Study of the Liver</aucorp><aucorp>Panel members</aucorp><aucorp>EASL Governing Board representative</aucorp><aucorp>European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>EASL recommendations on treatment of hepatitis C: Final update of the series</atitle><jtitle>Journal of hepatology</jtitle><addtitle>J Hepatol</addtitle><date>2020-11</date><risdate>2020</risdate><volume>73</volume><issue>5</issue><spage>1170</spage><epage>1218</epage><pages>1170-1218</pages><issn>0168-8278</issn><eissn>1600-0641</eissn><abstract>Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, as well as developments in diagnostic procedures and improvements in therapy and prevention. These therapies make it possible to eliminate hepatitis C as a major public health threat, as per the World Health Organization target, although the timeline and feasibility vary from region to region. These European Association for the Study of the Liver recommendations on treatment of hepatitis C describe the optimal management of patients with recently acquired and chronic HCV infections in 2020 and onwards.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>32956768</pmid><doi>10.1016/j.jhep.2020.08.018</doi><tpages>49</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0168-8278
ispartof Journal of hepatology, 2020-11, Vol.73 (5), p.1170-1218
issn 0168-8278
1600-0641
language eng
recordid cdi_proquest_miscellaneous_2444873987
source ScienceDirect Journals
subjects Chronic infection
Hepatitis C
Interferon
Liver diseases
Patients
Public health
title EASL recommendations on treatment of hepatitis C: Final update of the series
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T13%3A37%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=EASL%20recommendations%20on%20treatment%20of%20hepatitis%20C:%20Final%20update%20of%20the%20series&rft.jtitle=Journal%20of%20hepatology&rft.au=Pawlotsky,%20Jean-Michel&rft.aucorp=Clinical%20Practice%20Guidelines%20Panel:%20Chair&rft.date=2020-11&rft.volume=73&rft.issue=5&rft.spage=1170&rft.epage=1218&rft.pages=1170-1218&rft.issn=0168-8278&rft.eissn=1600-0641&rft_id=info:doi/10.1016/j.jhep.2020.08.018&rft_dat=%3Cproquest_cross%3E2486864333%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c494t-4f385e039712fd00103ad9f2afdc0cd75b99512d094b1174ecbd58f782465f203%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2486864333&rft_id=info:pmid/32956768&rfr_iscdi=true